Anticoagulants Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), by Route of Administration (Injectable Anticoagulant and Oral Anticoagulant), and by Application (Stroke, Atrial Fibrillation, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), and Others)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020–2029

                                          
Abstract
                    
The report covers a forecast and an analysis of the anticoagulants market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints of the anticoagulants market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the anticoagulants market on a global and regional level.

In order to give the users of this report a comprehensive view of the anticoagulants market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis to give a broader overview of the key players in the anticoagulants market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the anticoagulants market on a global and regional basis.

The study provides a decisive view of the anticoagulants market based on drug class, route of administration, application, and region. By drug class, the anticoagulants market is segmented into NOACs, heparin and LMWH, vitamin K antagonist, and others. The NOACs is sub-segmented into bevyxxa, eliquis, lixiana and savaysa, pradaxa, and xarelto. The route of administration segment is divided into injectable anticoagulant and oral anticoagulant. The application segment is segmented into stroke, atrial fibrillation, pulmonary embolism (PE), deep vein thrombosis (DVT), and others.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further fragmented into major countries including the U.S., Germany, France, UK, China, Japan, India, and Brazil.

Some players of the global anticoagulants market are Bayer AG, Aspen Holdings, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer, Inc., Sanofi S.A., Johnson & Johnson, and Portola Pharmaceuticals, Inc., among others.

This report segments the global anticoagulants market as follows:

Global Anticoagulants Market: By Drug Class

	NOACs
	
		Bevyxxa
		Eliquis
		Lixiana and Savaysa
		Pradaxa
		Xarelto
	
	
	Heparin and LMWH
	Vitamin K Antagonist
	Others

Global Anticoagulants Market: By Route of Administration

	Injectable Anticoagulant
	Oral Anticoagulant

Global Anticoagulants Market: By Application

	Stroke
	Atrial Fibrillation
	Pulmonary Embolism (PE)
	Deep vein thrombosis (DVT)
	Others

Global Anticoagulants Market: By Region

	North America
	
		U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	Middle East and Africa